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Solid Organ Transplantation
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1 UCLA Immunogenetics Center, University of California Los Angeles, Los Angeles, CA, USA, 2 Department of Pathology and 
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Long-term outcomes in solid organ transplantation are constrained by the development 
of donor-specific alloantibodies (DSA) against human leukocyte antigen (HLA) and other 
targets, which elicit antibody-mediated rejection (ABMR). However, antibody-mediated 
graft injury represents a broad continuum, from extensive complement activation and 
tissue damage compromising the function of the transplanted organ, to histological 
manifestations of endothelial cell injury and mononuclear cell infiltration but without 
concurrent allograft dysfunction. In addition, while transplant recipients with DSA as a 
whole fare worse than those without, a substantial minority of patients with DSA do not 
experience poorer graft outcome. Taken together, these observations suggest that not 
all DSA are equally pathogenic. Antibody effector functions are controlled by a number 
of factors, including antibody concentration, antigen availability, and antibody isotype/
subclass. Antibody isotype is specified by many integrated signals, including the antigen 
itself as well as from antigen-presenting cells or helper T cells. To date, a number of 
studies have described the repertoire of IgG subclasses directed against HLA in pre-
transplant patients and evaluated the clinical impact of different DSA IgG subclasses 
on allograft outcome. This review will summarize what is known about the repertoire of 
antibodies to HLA and non-HLA targets in transplantation, focusing on the distribution 
of IgG subclasses, as well as the general biology, etiology, and mechanisms of injury of 
different humoral factors.
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iNTRODUCTiON
The clinical significance of antibody-mediated rejection (ABMR) to transplant outcome is now 
widely established across solid organ transplants. The recent introduction of solid-phase single 
antigen antibody testing by Luminex enabled detection of donor-specific antibodies with signifi-
cantly greater sensitivity than had been previously available. Advances in T cell immunosuppression 
have significantly reduced T cell-mediated rejection as a cause of graft loss in medication adherent 
patients; consequently, antibody-mediated rejection has emerged as the leading cause of allograft 
failure (1).
Transplant recipients may be transplanted with either preformed donor-specific antibodies (DSA) 
that were generated by prior allosensitization events, such as pregnancy, transfusion, or transplanta-
tion, or develop DSA de novo after transplantation. Wiebe and colleagues reported (2) that low-risk 
renal transplant recipients develop de novo DSA at a rate of about 2% per year, appearing usually 
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around 2 years post-transplant. By 12 years post-transplant, the 
final incidence of DSA was 27%. Similar rates of de novo DSA 
were reported by Everly et  al., wherein 25% of patients had 
DSA by 10  years post-transplant (3). Pediatric and adult heart 
transplant recipients developed de novo DSA with an incidence 
of about 30–40% by 10 years post-transplant (4–6). Liver (7–9), 
lung (10, 11), pancreas (12, 13), and bowel (14, 15) transplant 
recipients also develop donor-specific human leukocyte antigen 
(HLA) antibodies.
Overall, DSA are seen in ~20% of solid organ transplant 
recipients and are a significant clinical factor in transplant out-
comes. Diagnostic criteria for ABMR vary slightly across solid 
organs, although endothelial cell injury, complement deposition, 
and mononuclear cell infiltration are recurrent manifestations. 
In renal transplants, acute ABMR is defined by histological 
evidence of tissue injury, such as microvascular inflammation 
(MVI) or arteritis, with or without complement C4d staining, 
and serological evidence of DSA (16, 17). Chronic rejection of 
renal allografts may also be triggered by donor-specific antibod-
ies and is characterized by transplant glomerulopathy, capillary 
basement membrane duplication or fibrosis, and MVI (17). In 
cardiac allografts, histologic changes, including endothelial cell 
activation and intravascular CD68+ macrophages, as well as 
complement activation detected by C4d or C3d deposition, are 
included in the diagnosis of pathologic ABMR (18, 19). ABMR 
in lung (20), pancreas (21), and liver (22) allografts also include a 
combination of C4d staining, mononuclear cell infiltration, and 
histological assessment of microvessel endothelial cell activation.
Transplant recipients developing DSA to polymorphic 
HLAs exhibit significantly worse graft survival and rejection 
rates. Allograft loss was higher in renal transplant patients who 
developed de novo DSA compared with patients who did not 
and had no dysfunction, and interestingly, patients could be 
further stratified by concurrent clinical ABMR at the time of 
DSA appearance. Those with subclinical DSA fared worse in the 
long-term than those without any DSA, but significantly better 
than those who had clinical ABMR at the detection of DSA, all of 
who lost their allografts by 8 years after the appearance of DSA. 
While non-adherence and delayed graft function (DGF) were 
significant predictors of graft loss, the strength or MFI of DSA 
was not itself a strong predictor (2, 23). Pediatric heart transplant 
recipients with DSA have higher incidences of cardiac allograft 
vasculopathy (CAV), also called transplant coronary artery dis-
ease (TCAD), compared to those without DSA, more rejection 
episodes, and lower graft survival at 5 years (5, 6). In adult heart 
transplant recipients, DSA is also an independent predictor of 
patient survival (4). Many studies have also demonstrated a clear 
decrement in outcome and graft survival among patients with 
antibody to non-HLA targets, such as major histocompatibility 
complex class I chain-related gene A (MICA) (24–27).
In spite of overwhelming evidence that patients with DSA tend 
to fare worse as a group than those without, these same stud-
ies have consistently shown that up to half (range 20–50%) of 
patients with HLA DSA do not experience poorer graft outcomes, 
including rejection incidence and graft loss, compared to their 
DSA− counterparts, at least to the endpoints reported (5, 6, 28–30). 
Indeed, even among DSA+ patients with adverse outcomes, there 
is a spectrum from subclinical, “indolent” antibody-mediated 
graft injury to clinically manifested acute antibody-mediated 
rejection to devastating hyperacute rejection. This has led to the 
hypothesis that not all antibodies are equally pathogenic and 
that identification of antibody features controlling graft injury 
might enable further stratification of patients with DSA who are 
at risk for rejection and allograft failure. Certainly, the titer of 
antibody is important for the degree of graft injury. The affinity of 
an antibody for its antigen and the effector functions an antibody 
can engage are also likely to be relevant to its “pathogenicity” in 
antibody-mediated allograft injury. Such diversity in antibody 
function is controlled in large part by the antibody’s isotype 
and subclass. This review will discuss the function of different 
IgG subclasses relevant to graft injury, the subclass repertoire of 
HLA and non-HLA antibodies found in transplantation, and the 
generation of antibodies of various isotypes and subclasses.
DiveRSiTY OF eFFeCTOR FUNCTiONS 
AMONG igG SUBCLASSeS
The heavy chain constant regions of human IgG are more than 
90% homologous, with variation mostly localizing to the CH2 
domain and hinge regions. Not coincidentally, these are the 
locations for Fc-mediated effector engagement, chiefly bind-
ing to FcγRs and complement C1q. Immunoglobulin effector 
functions are engaged by the Fc portion of IgG and include 
complement-dependent cytotoxicity (CDC), opsonization, 
antibody- dependent cell-mediated cytotoxicity (ADCC), and 
antibody-dependent cell-mediated phagocytosis. IgG subclasses 
vary in the length and flexibility of their hinge region, with IgG2 
and IgG3 representing opposite ends of the spectrum. The hinge 
region is the shortest and most rigid in IgG2, while IgG3 has 
a uniquely long hinge region that is quite flexible, promoting 
increased availability to the binding sites for FcγR and C1q. Studies 
optimizing effector functions of therapeutic antibodies have also 
pinpointed key amino acid residues, which control affinity of the 
Fc region for FcγRs and for complement components.
IgG4 has been called an “odd antibody” due to its unique 
structural properties (31). IgG4 can form Fab arm monomers 
(half-molecules) that are monovalent. This feature is thought 
to represent a self-limiting process of the humoral immune 
response, as these monomers can block better effector subclasses 
from binding to antigen. Another consequence of reduced stabil-
ity in the IgG4 Fc tail is its reported ability to exchange Fab arms 
and form bispecific antibody molecules.
Affinity, Persistence, and Localization
Some evidence points to differences in IgG subclass affinity for 
antigens. Berkowska et al. found that in peripheral blood B cells, 
transcripts of IGHG2 and IGHG4 contained higher loads of 
somatic hypermutation in the variable regions compared with 
IGHG1 and IGHG3 (32). Thus, “indirect” sequential switching 
to IgG2 and IgG4 might indicate more germinal center reactions 
and longer activity of the enzyme activation-induced cytidine 
deaminase (AID). It might be surmised from this work that later 
subclasses IgG2 and IgG4 result from more extensive affinity 
FiGURe 1 | Agonistic signaling by antibodies. (A) Bivalent IgG of any 
subclass may dimerize or crosslink target antigens, such as HLA molecules. 
Many studies have demonstrated that HLA ligation on endothelial cells, 
vascular smooth muscle cells, and antigen-presenting cells induces 
intracellular signaling via tyrosine kinases. HLA signaling promotes cell 
proliferation, migration, and increased expression of survival proteins such as 
Bcl-2 and Bcl-XL. In addition, HLA cross-linking triggers exocytosis of 
endothelial vesicles called Weibel–Palade bodies, which contain vasoactive 
mediators and the adhesion molecule P-selectin. Increased cell surface 
P-selectin in turn supports increased adherence of leukocytes. (B) Anti-AT1R 
antibodies act agonistically, binding to an epitope on this multi-pass 
transmembrane receptor and stimulating increased IL-8 expression and 
tissue factor production. AT1R agonism is also implicated in malignant 
hypertension in a variety of diseases as well as transplantation. (C) Some 
molecules of human IgG4 have been shown to form monovalent Fab arms 
that may cross-dimerize with other clones of IgG4 to create bispecific 
antibodies. Although not experimentally demonstrated, in theory, such 
monovalent and bispecific IgG4 molecules would be incapable of cross-
linking HLA and might in fact block other subclasses from binding.
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maturation compared with upstream IgG1 and IgG3 (32), as 
was suggested by early work evaluating IgG subclass response 
and affinity in human KLH immunization (33). These results are 
similar to findings that mutation loads were highest in antigen-
specific IgG4 compared with other subclasses after secondary 
immunization with Meningococcus (34). Studies of murine IgG 
subclasses reveal similar differences in affinity. One study put 
forth the hypothesis that the constant region itself affected affinity 
for antigen, where IgG of different subclasses, but with identical 
variable regions, displayed different affinity for antigen (35–37). 
Antibody affinity (i.e., variable region variants) for antigen 
appears to be important for its ability to provoke Fc-mediated 
effector functions such as ADCC, discussed below (38, 39).
IgG3 has the shortest half-life, of about a week, while the other 
subclasses have a half-life of about 3 weeks. This is due to an arginine 
at amino acid position 435 of IgG3, rather than a histidine which 
is present in other subclasses, significantly increasing its affinity 
for the neonatal Fc salvage receptor (FcRn) (40). Interestingly, 
although many allotypes of immunoglobulin have been identified 
to date (41), only polymorphisms in IgG3 which revert this position 
to histidine demonstrate any change in function, increasing the 
half-life of these alleles of IgG3 (42). The affinity of IgG subclasses 
for FcRn is of relevance to antibody-mediated diseases of the fetus 
and newborn. In addition to variation in placental transport, the 
isotypes of antibodies also differ in their ability to diffuse into the 
host’s own tissues, which serves to compartmentalize the humoral 
response. IgM has poor diffusion due to its size, whereas IgA is 
found in secretions and at epithelial surface. IgG is predominantly 
in circulation but also can diffuse into the tissues. Traditionally, 
IgG3 was described to have poor transport across the placenta due 
to its low affinity for FcRn; however, it was recently emphasized 
that the majority of IgG3 alleles represented in Western study 
populations were R435, in contrast to the H435 found frequently 
in other groups. Therefore, ethnic differences in IgG allotypes are 
also important to antibody effector functions.
Agonism
A key function of antibodies is to block their target, neutralizing 
it as with viruses. IgG, being bivalent, can also dimerize its target 
antigen and stimulate inhibitory or agonistic signaling depending 
on the target. Our group and others have shown that antibodies 
to HLA class I molecules also activate intracellular signaling cas-
cades in vascular endothelial and smooth muscle cells, resulting in 
increased cell proliferation, migration, and recruitment of leuko-
cytes (43–54) (Figure 1A). Less is known about agonistic signal-
ing of antibodies against HLA II molecules. In antigen-presenting 
cells, HLA-DR ligation by antibodies mimics TCR engagement, 
and induces cell activation and proliferation (55–59). Endothelial 
cells expressing HLA-DR also respond to anti-HLA-DR antibod-
ies by increased allostimulation of T cells (60, 61). Transcriptome 
studies of renal transplant biopsies undergoing ABMR have 
revealed an enriched endothelial-specific signature, paralleling 
these in vitro studies (62). Antibodies to the angiotensin II type 
1 receptor (AT1R) agonistically activate AT1R signaling and 
induce detrimental effects on vascular endothelial phenotype and 
function (63, 64) (Figure 1B). AT1R antibodies are implicated 
in systemic sclerosis (SSc), preeclampsia (65), hypertension (66), 
and allograft dysfunction (67, 68). Auto-antibodies to endothelial 
cells [anti-endothelial cell antibodies (AECA)], against yet mostly 
unidentified antigens, activate endothelia to express a variety of 
adhesion molecules (69).
Functional target agonist activity is presumably independent 
of the Fc portion of the antibody, as stimulation of endothelium 
with the F(ab′)2 fragment still elicits these functional changes. 
Interestingly, Stein et al. demonstrated that a chimeric anti-HLA-
DR hIgG4 (engineered to stay bivalent, not form half-molecules), 
while not able to induce Fc-mediated functions such as comple-
ment activation or ADCC of tumor B cells, significantly increased 
intracellular Akt signaling, suppressed proliferation, and induced 
apoptosis at a comparable level as the parental anti-HLA-DR (70). 
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So, while generally incapable of eliciting Fc-mediated effector 
functions, if bivalent, IgG4 can still cross-link HLA molecules 
and provoke intracellular signaling cascades and target cell phe-
notype changes. Therefore, it could be surmised that signaling 
of HLA and non-HLA targets in the allograft can be induced by 
all subclasses of immunoglobulin, with the possible exception 
of monovalent or bispecific forms of IgG4 (Figure 1C). The dif-
ferential ability of IgG subclasses to induce agonistic signaling 
remains to be explored.
Complement-Dependent Cytotoxicity  
and inflammation
Arguably, the most studied effector function of antibodies in 
transplantation is the ability to activate complement. Histological 
detection of the complement split product C4d within allograft 
vasculature has been central to the diagnostic criteria of ABMR 
for decades.
The complement system is ancient part of the innate immune 
system culminating in activation of terminal split products that 
are highly inflammatory and can cause target cell death (whether 
mammalian or pathogen). Three arms of the complement sys-
tem, lectin, alternative, and classical pathways are triggered by 
different stimuli, but all converge on the central regulator C3. 
Canonically, the classical pathway is activated by immunoglobu-
lin. The details of the classical complement pathway have been 
excellently reviewed elsewhere (71); a brief summary can be 
found in Figure 2.
Activation of complement is balanced by complement regula-
tory proteins, both soluble and cell surface, and self-limiting due to 
cleavage of active mediators. Such regulatory proteins, including 
decay-accelerating factor (DAF, CD55), MCP (CD46), and CD59, 
expressed on endothelial and other cells, and serum C1-INH and 
Factor H, limit inflammation and confer protection of host cells 
during complement activation. DAF acts to inhibit C3 activation 
downstream of C4 and C2 and upstream of C3 and C5. Anti-
EGFR IgG3 promoted deposition of C1q and C3b on target tumor 
cells, as well as generation of upstream C4a, but failed to result 
in the generation of C3a or C5a due to high expression of CD55 
on the tumor cells (72), demonstrating the resistance of cells to 
terminal complement activation when they express complement 
regulatory proteins. Indeed, deficiency of the complement regula-
tory protein DAF abolishes protection of corneal allografts from 
alloimmune destruction (73) and exacerbates rejection of cardiac 
allografts in mice (74, 75). Interestingly, among human cardiac 
transplant recipients with active C4d+ antibody-mediated rejec-
tion, those without concurrent dysfunction exhibited increased 
expression of DAF compared to patients who had ABMR and 
allograft dysfunction (76). These studies underscore the protec-
tive role of complement regulatory proteins in transplantation.
The four subclasses of IgG vary in their affinity for C1q 
(Table 1). IgG3 is a potent stimulator of complement activation, 
with IgG1 following closely behind. IgG2, although typically cited 
as non-complement fixing, in fact can fairly efficiently bind to C1 
and activate complement under conditions of high antigen den-
sity and/or high antibody titer. IgG4, in contrast, has nearly no 
detectable complement-activating properties. Experiments using 
subclass switch variants carrying the same variable regions have 
shown that IgG4 is a poor activator of human CDC compared 
with IgG1 and IgG3, with IgG2 having intermediate complement 
activity at higher antibody concentration (70, 77). Interesting 
murine models of ABMR showed that non-complement-fixing 
subclasses of antidonor IgG were able to augment complement 
activation by the stronger complement-fixing subclasses (78).
It is worthwhile to note that the CDC cross-match assay 
used in transplantation employs rabbit complement rather than 
human complement. Due to heterophilic antibodies and inter-
species interactions between human IgG subclasses and rabbit 
complement proteins, the CDC is not necessarily reflective of true 
complement-activating capacity of human antibodies. Indeed, 
human IgG2, while not a good activator of the classical human 
complement cascade, effectively triggers activity of rabbit com-
plement (79). Nevertheless, the cytotoxic cross-match generally 
does reveal antibodies with very high titer and correlates well 
with clinical outcomes (80).
Terminal complement activation ultimately triggers cell 
death, and this outcome has been a focus early in transplantation 
due to its dramatic and devastating injury to the allograft (81) 
(Figure 2A). Given the protection of the graft endothelium by 
constitutive expression of complement regulatory proteins, it is 
conceivable that only very high titers of strongly complement-
fixing antibodies can overcome inhibition to cause endothelial 
cytolysis. Hyperacute rejection is now a rare event due to 
improved sensitivity of antibody and cross-match tests and gen-
eral avoidance of strong donor-specific antibodies. Consequently, 
there has been increased interest in the upstream mediators of 
the complement system, and the role of “complement-dependent 
inflammation.” Anaphylatoxins and opsonins C4a, C3a, C3b, 
and C5a are all critically important in regulating innate inflam-
mation, as well as modulation of adaptive immunity. C4a, C3a, 
and C5a are chemoattractant for neutrophils and monocytes (82, 
83) (Figure  2B). Endothelial cells respond to C5a by releasing 
intracellular vesicles containing adhesion molecules and vasoac-
tive mediators (45, 84), and to sublytic deposition of membrane 
attack complex (MAC) by activation of non-canonical NFκB 
and upregulation of inflammatory genes including VCAM-1 
and E-selectin (85, 86) (Figure  2C). Complement may also be 
implicated in transplant vasculopathy, although arteriopathy also 
develops in C3-deficient mice (87, 88).
The regulation of adaptive immunity by complement, particu-
larly complement C3 components, has been revealed by several 
studies. When B cells encounter opsonized antigen coated with 
C3d, coligation of the BCR with complement receptors CD21 
and CD35 lowers the threshold for B cell activation and enhances 
humoral immunity [reviewed in Ref. (89)]. Heeger and colleagues 
have expanded our understanding of how complement modulates 
T cell responses [reviewed in Ref. (90, 91)]. For example, C3a 
and C5a enhance T cell proliferation and activation, as well as 
antigen-presenting cell activation.
it is Unclear whether In Vitro Complement 
Fixation is a Reliable Predictor  
of Rejection or Graft Loss
Investigators have also utilized modifications of the HLA 
solid-phase assays to infer the ability of antibodies to activate 
FiGURe 2 | Complement-dependent cytotoxicity and inflammation. (A) High titers of antidonor HLA antibodies, particularly of the efficient complement-fixing 
subclasses IgG1 and IgG3, may promote terminal classical complement pathway activation. Complement activation must overcome the regulatory factors and push 
complement activation to terminal MAC formation and cell damage. (B) Lower titers of antibody or less efficient complement-fixing subclasses, such as IgG2, may 
result in truncated complement activation, with upstream anaphylatoxin release and opsonin deposition. The initiator C1 complex, composed of globular C1q, 
embedded with catalytically active C1r and C1s, recognizes the Fc portion of IgM and most of the IgG subclasses, triggering a conformational change in the 
hexameric shape of the C1 complex. This activates the autocatalytic cleavage of C1r, which then activates C1s. C4 and C2 are cleaved by C1s, forming C4a and 
C2a split products that generate the C3 convertase. C3 convertase cleaves C3 protein into C3a, a soluble inflammatory protein, and C3b, which is covalently bound 
to the cell surface. C3b may be further cleaved to C3d or form the C5 convertase. Terminal activation of the C5 convertase cleaves C5 protein, generating the 
potent anaphylatoxin C5a and the membrane-bound C5b. C5b recruits C6–9 proteins to form the membrane attack complex (MAC), disrupting membrane integrity. 
Complement regulatory proteins DAF and CD59 at the host cell surface restrain activation of the complement cascade at the two key amplification steps, C3 
cleavage and C5 cleavage. (C) Many cells express receptors for the soluble and membrane-bound complement split products. Endothelial cells respond to C5a by 
upregulating P-selectin, and to sublytic concentrations of MAC by activation of non-canonical NFκB pathways, adhesion molecule, and cytokine upregulation. 
Monocytes and neutrophils express C3a and C5a receptors, which participate in chemotaxis of myeloid cells. Complement receptor 2 (CR2) is a component of the 
BCR that binds to opsonized, C3d-coated antigen. CR2 signaling enhances the BCR signal and lowers the threshold for B cell activation.
5
Valenzuela et al. IgG Subclasses in Transplantation
Frontiers in Immunology | www.frontiersin.org October 2016 | Volume 7 | Article 433
TABLe 1 | Summary of igG subclass effector functions.
Binding to FcγR alleles
ADCC 
(NK)
Complement 
activation
 
Antigen recognized
FcγRi  
CD64
FcγRii  
CD32a-H
FcγRii  
CD32A-R
FcγRii  
CD32b
FcγRiii 
CD16a-v
FcγRiii 
CD16a-F
FcγRiii 
CD16b-NA1
FcγRiii 
CD16b-NA2
IgG1 +++ +++ T-dep protein +++ ++ +++ + +++ ++ +++ +++
IgG2 + +b Carbohydrate and T-dep protein − ++ + − + − − −
IgG3 +++ +++ T-dep protein +++ ++ +++ ++ +++ +++ +++ +++
IgG4 a − T-dep protein +++ + + ± ++ − − −
aADCC elicited by IgG4 depends on the glycosylation pattern of the Fc region.
bComplement activation by IgG2 depends on the titer of antibody and the density of antigen.
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complement, measuring binding of complement components 
C1q (30, 92–95), C4d (96–100), or C3d (96, 101, 102) to single 
antigen beads and to cells. However, reports conflict as to whether 
such assays provide better resolution of antibody pathogenicity 
and indeed ability to initiate the complement cascade in these 
in vitro assays seems to still be tied to antibody titer. Certainly, 
the strength or titer of antibody seems to be linked with its 
pathogenicity. For example, as recognized early in solid organ 
transplantation, very high titers of HLA DSA (that can cause a 
positive CDC cross-match) can trigger hyperacute rejection and 
early graft dysfunction. Increasing strength of DSA is associated 
with lower graft function in renal transplant recipients (103). 
Zeevi et al. found that high titers of HLA DSA were able to fix 
C1q and were associated with early ABMR in heart transplant 
patients (104). In contrast, Smith et  al. found that both non-
complement-fixing and complement-fixing DSA (measured by 
C4d deposition on single antigen beads) were associated with 
reduced heart transplant patient survival (4) and did not con-
clude that complement activation in vitro was a useful predictor 
of more pathogenic DSA. In studies of kidney transplantation, 
Crespo et al. reported that C1q-fixing DSA had higher MFIs but 
that C1q positivity did not correlate with outcome in renal trans-
plant recipients, whereas other groups have uncovered an added 
predictive value of C1q-positive DSA in renal allograft survival 
(30, 94, 105–107). In conclusion, there is no clear consensus 
on whether donor-specific antibodies which fix complement in 
in vitro assays better discriminate those that are detrimental to 
allograft survival; it does appear, though, that antibodies which 
do not bind to complement in these assays are still relevant to 
graft outcome.
FcγR-Mediated Functions
Antibodies can engage Fc receptors present on most hemat-
opoietic cells. FcγRs are highly selective in their affinity for IgG 
subclasses (Table 1) [reviewed in Ref. (108, 109)]. The receptors 
for IgG, the FcγR family, are expressed on myeloid and NK cells 
as well as B cells. All myeloid cells express activating FcγRs, and 
some coexpress an inhibitory FcγR. There are three major classes 
of human FcγRs, FcγRI (CD64), FcγRII (CD32), and FcγRIII 
(CD16), which are differentially distributed on innate and adap-
tive effector cells. FcγRI is an activating receptor with high affinity 
for both monomeric and complexed IgG and is present on the 
major population of monocytes, as well as macrophages and acti-
vated neutrophils. FcγRII has two subtypes, FcγRIIa, expressed 
on monocytes, macrophages, and highly on neutrophils, and the 
inhibitory FcγRIIb. FcγRII has comparably lower affinity than 
FcγRI for monomeric IgG but binds efficiently to high avidity 
ligands of complexed or immobilized IgG. FcγRIIIa is expressed 
on NK cells and a minor population of monocytes, while FcγRIIIb 
is expressed on neutrophils.
Polymorphisms in the FcγR system shape individual sus-
ceptibility to infectious disease, autoimmunity, and response 
to antibody-based therapeutics (110–115). While FcγRI has no 
known polymorphism, FcγRIIa, FcγRIIIa, and FcγRIIIb are each 
dimorphic, with two alleles having different affinities for IgG 
(116). For example, the FcγRIIa alleles H131 and R131 differ 
in their affinity for IgG1, with H131 having higher affinity and 
the ability to bind to IgG2. Taken together, it is probable that 
the transplant recipient’s own constellation of FcγR alleles offset 
or augment the effects of the subclass repertoire during FcγR-
mediated injury.
Opsonization and Phagocytosis
Antibodies act in concert with complement activation to mark 
target cells and microbes for uptake by phagocytes, a process 
called opsonization. FcγRs work with complement receptors to 
elicit phagocytosis. IgG3 most potently induced opsonization of 
meningococci (chimeric antibodies + human complement) and 
respiratory burst in PMN induced, with IgG1 slightly less potent 
and very activity little with IgG2 or IgG4 (77). Therefore, IgG3 
and IgG1 are typically thought of as the most potent opsonizing 
antibodies.
Antibody-Dependent Cell-Mediated 
Cytotoxicity
Engagement of FcγRs activates ADCC (Figure  3). NK cells 
express CD16A and CD16C. In NK cells, FcγR cross-linking initi-
ates intracellular signaling leading to polarized release of perforin 
and granzyme, causing death of the antibody-coated target cell. 
While myeloid cells, such as macrophages, also carry out ADCC, 
the mechanisms are less clear. Typically, IgG1 and IgG3 are the 
most efficient activators of NK cell-mediated ADCC due to the 
higher affinity of FcγRIIIa for these subclasses (Table 1). Not only 
is IgG4 ineffective at eliciting ADCC but also has been shown 
to actively block monocyte-mediated antitumor ADCC when 
present in equal concentrations with IgG1, through competitive 
binding to FcγRI (117).
FiGURe 3 | FcγR-mediated effector functions. (A) Monocytes and 
neutrophils express FcγRs, which bind preferentially to different IgG 
subclasses. FcγR cross-linking by myeloid cells induces activation and 
mediates antibody-dependent cell-mediated cytotoxicity (ADCC), 
phagocytosis (ADCP), and augments recruitment of leukocytes from the 
blood. In general, IgG1 and IgG3 efficiently bind to most FcγR isoforms 
expressed by monocytes and neutrophils. IgG4 can bind quite well to FcγRI 
(CD64), and IgG2 is bound by an allelic variant of FcγRIIa (CD32a, H131).  
(B) NK cells express FcγRIII (CD16). Engagement of FcγRIII by antibody-
coated target cells induces ADCC via degranulation and release of perforin/
granzyme. Cross-linking of FcγRIII on NK cells also upregulates the 
inflammatory cytokines IL-12, IFNγ, and TNFα.
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There is limited evidence directly demonstrating that ADCC 
is actually occurring within allografts during antibody-mediated 
rejection. How ADCC might manifest histologically is unclear. 
Early work attempted to prove that alloantibodies were able to 
induce ADCC against allogeneic endothelial cells, using in vitro 
assays. The authors showed that sera of only a few post-transplant 
patients were able to induce lysis of cultured endothelial cells 
by NK cells (118). A follow-up study suggested that patients 
whose serum was capable of inducing ADCC against cultured 
endothelial cells had more vascular rejection and graft loss than 
patients without ADCC activity (119). Experimental models have 
shown that NK cells are critical for chronic antibody-mediated 
rejection in the mouse [reviewed in Ref. (120, 121)]. Hidalgo et al. 
identified NK transcript signatures in renal transplant biopsies 
from patients with rejection, particularly late antibody-mediated 
rejection (122, 123). Taken together, these results point to a role 
for NK cells in antibody-mediated rejection beyond ADCC.
FcγR Signaling
We and others have shown that FcγR signaling in monocytes and 
neutrophils participates in the leukocyte recruitment cascade 
(124, 125). Concurrent engagement of FcγRs and adhesion 
molecules augments firm adhesion of myeloid cells through 
increased activation of integrins, enabling increased capture 
of FcγR-bearing leukocytes by antibody-coated endothelium 
(Figure 3). FcγR signaling also influences macrophage differen-
tiation, dendritic cell maturation, and enables prolonged antigen 
presentation. Thus, subclasses that more effectively engage FcγRs 
on macrophages, neutrophils, and dendritic cells should be better 
capable of inducing FcγR signaling in these cells.
ANTiBODY SUBCLASSeS  
iN TRANSPLANTATiON
Different routes of allosensitization trigger distinct patterns of IgG 
subclasses directed against HLA, which supports the paradigm 
that the inflammatory milieu upon antigen exposure, as well 
as the antigen itself, controls selection of subclass. Intriguingly, 
memory formation also appears to differ after various allosensiti-
zation events, pointing to immunologically distinct mechanisms 
of immunization against HLA and MICA through transfusion, 
pregnancy, and transplantation.
Assays to identify HLA Antibodies
Cell-based and solid-phase testing for HLA antibodies classically 
identify antibodies of the IgG isotype as donor-specific IgG HLA 
antibodies. The classical complement-dependent cytotoxic assay 
identifies strong anti-HLA IgG antibodies that bind HLA on the 
surface of the target cell and initiate the complement cascade 
culminating in the formation of the MAC complex and cell death 
identified by fluorescent microscopy. The T and B flow cross-
match identifies anti-HLA IgG binding to the surface of T or B 
cells and quantitates the median channel shift over cells incubated 
with a negative control serum. In comparison to the CDC, the T 
and B flow cross-match is more sensitive and quantitative allow-
ing for the identification of antibodies that are weak/moderate 
in strength. Solid-phase assays identify HLA antibody that bind 
HLA antigen bound to a plate (ELISA) or bead (single antigen 
bead) in a cell-free environment. The single antigen bead assay 
currently allows the most quantitative and sensitive measurement 
of HLA IgG antibodies identified by Luminex technology.
Antibody Subclasses in Allosensitization 
(Pretransplant)
Significant effort has been contributed to determining the IgG 
subclass repertoire in pre- and post-transplant patients (Table 2). 
To achieve these goals, laboratories have developed protocols that 
modify the traditional single antigen bead assay by replacing the 
IgG detection antibody with subclass-specific clones for IgG1–4 
(126–130). The data are consistent in showing IgG1 as the pre-
dominant Ig subclass in pre- and post-transplant sera, and have 
attempted to associate specific subclasses with sensitizing events, 
allograft pathology, and loss (see below) (126–130).
Allosensitization can occur following immunizing events such 
as pregnancy, transfusion, or transplant. In a study of sensitization 
to HLA antigens using subclass-specific IgG1–4 reporter antibod-
ies in the single antigen bead assay, Lowe and colleagues showed 
that the subclass repertoire following unequivocal immunization 
to HLA antigens through pregnancy and transplantation is het-
erogeneous and dominated by the IgG1 subclass in 38 patients 
(128). IgG2 secondarily dominant following blood transfusion 
and failed transplant, while IgG3 was secondarily dominant 
following pregnancy. Generally, blood transfusion stimulated a 
restricted, IgG1-dominated response to HLA antigens.
TABLe 2 | Summary of different methods for detecting igG subclasses against HLA and non-HLA targets.
 
Reference
Organ/
target
 
Determinants of positive cutoff
Antibody 
source
Lefaucheur 
et al. (130)
Renal/HLA For each IgG subclass antibody and each single antigen bead, the mean MFI values from 4 non-sensitized healthy male 
controls +5 SD, and if that value was <500 MFI; the IgG 1–4 reactivity was considered positive if the normalized MFI was ≥500
Southern 
Biotech
Khovanova 
et al. (129)
Renal/HLA >5× the greater than the average negative control bead MFI in the single antigen bead assay of all tests for each subclass. 
IgG1: 120.6, IgG2: 72.0, IgG3: 62.7, IgG4:17.2
Southern 
Biotech
Lowe  
et al. (128)
Renal/HLA >5× the greater than the average negative control bead MFI in the single antigen bead assay of all tests for each subclass. 
IgG1: 120.6, IgG2: 72.0, IgG3: 62.7, IgG4:17.2
Southern 
Biotech
Kaneku  
et al. (127)
Liver/HLA Normalized trimmed MFI higher than 500 was defined as positive on the basis of binding patterns after validation and dilution 
experiments
Southern 
Biotech
Honger 
(126)
Renal/HLA A positive result was defined by a MFI value above a cutoff that was generated for each IgG subclass and for every individual 
bead by using four negative control sera from healthy non-sensitized and HLA antibody-negative men: cutoff MFI = mean 
NC1–4 + 3 SDs NC1–4. To determine the amount of IgG subclasses, we used the ratio above the corresponding cutoff (i.e., 
ratio = MFI IgG subclass divided by MFI cutoff)
Southern 
Biotech
Jackson  
et al. (131)
Endothelial  
cells
Median fluorescence values for IgG subclasses identified in test serum were normalized to values obtained when cells were 
incubated with normal control AB serum (Atlanta Biologicals, Norcross, GA, USA). IgG subclass analysis of HLA antibodies 
was assessed in the same manner using 10 ECP donors and pooled sera from high calculated panel reactive antibody (cPRA) 
transplant candidates
Southern 
Biotech
Griffiths  
et al. (132)
Renal/HLA For each IgG subclass and for every individual bead by using four negative control sera (NC1–4) from healthy, non-sensitized, 
and HLA antibody-negative cutoff MFI mean NC1–4 + 3 SDs NC1–4. To determine the amount of IgG subclasses, we used the 
ratio above the corresponding cutoff
Sigma
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The strength of pretransplant DSA is associated with ABMR 
and graft loss. As shown by Lefaucheur and colleagues using 
the traditional single antigen bead assay, the relative risk for 
ABMR increased significantly as the strength of preformed DSA 
increased (133). Patients with MFI of 3000–6000 or >6000 had 
greater than 60-fold or 100-fold risk, respectively, of developing 
AMR. Graft survival at 8 years after transplant among patients 
with preformed DSA >3000 MFI was only 60.6%, as compared 
to 78.4% for patients with preformed DSA strength of ~500–3000 
MFI and 82.5% for patients negative for preformed DSA (133).
Donor-Specific HLA Antibody Subclasses: 
Post-Transplant
Preliminary work, using subclass-specific IgG1–4 antibodies in 
flow cross-match or ELISA platforms, suggested that predomi-
nant expression of IgG1 in pretransplant sera was associated with 
acute rejection (134) and graft loss (132, 135). In a small study 
evaluating the IgG subclass of DSA using flow cytometry on 
donor spleen cells in kidney and liver recipients (136), one patient 
who lost the graft due to hyperacute rejection had high IgG3 
DSA pretransplant despite a negative CDC-XM, suggesting that 
high titers of this subclass are potent mediators of complement-
dependent rejection.
More recent data, using the subclass-specific modification of 
the single antigen assay, support the predominance of the IgG1 
subclass in transplant patient sera (126, 127). IgG2 and IgG4 do 
not typically constitute a large proportion of HLA DSA (137). 
Several groups have attempted to further define the various sub-
classes as predictive biomarkers of graft pathology and outcome 
(127, 129, 130). Lobashevsky et  al. analyzed the specificities as 
well as the subclasses of DSA pretransplant and post-transplant 
in three renal recipients using SAB modification with subclass 
secondaries in each patient, the proportion of different IgG 
subclasses were different against different antigens (138). One 
patient experienced rejection early post-transplant and had two 
DSA, both of which were about equal mixture of IgG1 and IgG2; 
the other two patients had good outcomes: one had IgG1, IgG2, 
and IgG4 DSA, whereas the other had predominantly IgG1. It is 
important to note that this paper highlights that each antigen can 
be recognized by multiple subclasses.
A cohort of post-liver transplant patients with chronic rejec-
tion and a group of patients without rejection were studied to 
determine if the presence of IgG subclass-specific DSA correlated 
with clinical state (127). The data showed that chronic rejec-
tion in liver transplant patients is correlated with the presence 
of DSAs of multiple subclasses, while normal graft function 
in the presence of DSA is correlated with DSA isolated to the 
IgG1 subclass. Furthermore, DSA of the IgG3 subclass was more 
closely associated with graft loss than DSA to other subclasses or 
no DSA. Everly et al. also found that the presence of IgG3 HLA 
DSA, particularly concurrent with IgM DSA, was predictive of 
allograft failure in renal transplant recipients (139).
Gao et  al. first observed that IgG4 was increased in most 
recipients post-transplant (136). In pre- and post-transplant sera 
from 80 sensitized renal transplant patients, pretransplant IgG4 
levels were predictive of acute ABMR in the first 30 days post-
transplant, while preformed IgG4 and post-transplant day 30 
IgG3 were associated with graft loss (129). In another study, sera 
from 125 consecutive renal transplant patients with DSA detected 
within the first year post-transplant evaluated for subclasses of IgG 
showed that IgG3 is associated with AMR, while IgG4 was associ-
ated with subclinical ABMR in protocol biopsies and late allograft 
injury (130). These data regarding the potential pathogenesis of 
IgG4 in renal transplant patients in the early post-transplant 
period are interesting as this subclass has been classically con-
sidered a marker of chronic antigen exposure produced due to 
“hyperimmunization” (140). The comment by Schaub et al. (141) 
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is right on point – the presence of later subclasses IgG2 and IgG4 
is suggestive of a more advanced humoral response with active 
T cell help. Donor-specific IgG4, despite its inability to activate 
complement, is correlated with poor graft outcome. Nevertheless, 
it is at this time difficult to dissect whether a predominance of 
IgG4 in any inflammatory disease, including transplantation, is 
due to the mechanism/pathogenicity of this subclass or is reflec-
tive of extensive antigen exposure and immune memory.
Given that most patients exhibit a mixture of IgG subclasses 
directed to HLA, several attempts have been made to evaluate 
whether grouping subclasses by presumed capacity to activate 
effector functions is able to further stratify risk. HLA DSA 
in sera from pre-kidney transplant patients were classified 
according to the presence of preformed DSA that are strong 
complement fixing (IgG1 and IgG3; n = 21/74 patients), weak/
non-complement fixing (IgG2 and IgG4; n = 4/74 patients), or 
a mixture of both (containing a mixture of IgG1–4; n = 46/74) 
(126). While a trend was observed implying that patients with 
exclusively weak/non-complement-fixing DSA had lower 
incidence of ABMR at 6 months post-transplant, the incidence 
and histologic phenotypes of ABMR in patients displaying 
strong complement-fixing DSA was not significantly different 
from those that displayed a mixture of weak/non-complement-
binding and strong complement-binding DSA. In a similar 
approach, Arnold et al. described the IgG subclass patterns of 
de novo DSA in adult renal transplant recipients by grouping 
subclasses together based on presumed complement activ-
ity. They observed that a majority of patients had exclusively 
“complement-fixing” IgG1 and IgG3, while the remainder had 
a mixture of complement-fixing and non-complement-fixing 
subclasses, with a very small percentage having IgG2 and IgG4 
alone. ABMR was more often observed in patients with a mix-
ture of subclasses than with IgG1/IgG3 only; however, there 
was no difference in graft survival between these groups (142). 
Interestingly, the DSA in patients with only IgG2 and IgG4 
were directed exclusively against HLA class II antigens. Finally, 
Freitas et al. found that most patients exhibit a mixture of IgG 
subclass directed against donor HLA-DQ antigens, and there 
was no significant difference in incidence of rejection compar-
ing patients who had IgG1 and IgG3 compared with those with 
a preponderance of IgG2 and IgG4 (95).
Non-HLA Antibodies
Antibodies to non-HLA antigens on the surface of the endothe-
lium or epithelium, aka, non-HLA antibodies, or AECA, have 
been identified with specificity to alloantigens, such as MICA 
or major histocompatibility complex class I chain-related gene 
B (MICB) (143, 144), or autoantigens, such as vimentin (145), 
cardiac myosin (CM), collagen V (ColV), agrin (146), endoglin, 
EGF-like repeats, Fms-like tyrosine kinase-3 ligand, ICAM-4 
(69), and AT1R (67). Currently, there are only a few tests in clini-
cal laboratories for the identification of non-HLA antibodies for 
transplant patients. Non-HLA antibodies to AT1R are measured 
by ELISA. Antibodies to MICA are measured using a MICA 
single antigen test (27). Donor-specific anti-endothelial cells can 
be measured by flow cytometry-based XM-ONE, which detects 
binding of IgG and IgM to peripheral blood endothelial cell 
precursors (147). While the isotypes and subclasses of antibodies 
to MICA are yet to be characterized, they do not appear to be 
predominantly complement fixing, at least in in vitro assays (148). 
Contradictorily, antibodies to MICA are found in both C4d+ and 
C4d− ABMR (149). Seminal work by Dragun et al. (67) showed 
that AT1R antibodies were present in renal transplant recipients 
with refractory vascular rejection but with no HLA DSA [sub-
stantiated by Reinsmoen et al. (150)], and the same group went 
on to show that these antibodies were predominantly IgG1 and 
IgG3 subclasses (151). Interestingly, however, histological mani-
festations of AT1R-mediated graft dysfunction do not typically 
include positive C4d staining, suggesting that injury via anti-
AT1R antibodies might be complement independent, despite a 
predominance of strongly complement-fixing subclasses. As 
mentioned above, bivalent antibodies may act agonistically; 
and clinically AT1R-mediated graft dysfunction can present 
with hypertension and histologically with MVI (152). Using 
XM-ONE, patients with positive endothelial progenitor cross-
match experienced increased rejection (majority were C4D− and 
classified as cellular rejection) and higher serum creatinine (153). 
AECA that bind ECP were found to be present in about 60% of 
patients tested (HLA DSA−) and were primarily of the IgG2 and 
IgG4 subtypes (69, 131, 154).
Limitations
Several caveats to the modification of single antigen testing to 
detect IgG subclasses warrant discussion. First, the IgG 1 and 2 
subclass-specific antibodies exhibit non-specific binding to single 
antigen beads coated with the alternate antigen. For example, 
the IgG1 subclass-specific antibody cross-reacts with the IgG2 
antigen at an MFI that is about 4.42% of the value observed 
when it specifically binds its target on an IgG1 coated bead (128). 
Cross-reactivity is observed between the IgG2 subclass-specific 
antibody and the IgG1 antigen ranging from 3 to 15%; however, 
the IgG3 and 4 antibodies appear to be less cross-reactive (126, 
128). Second, the IgG1–4 antibodies bind single antigen beads 
coated with their cognate antigen with different strengths 
(IgG1 >  IgG2 >  IgG3 >  IgG4), suggesting that the antibodies 
have different affinity for their target antigens (128). Third, the 
concentration of the different IgG subclasses cannot be directly 
compared to infer relative abundance of each subclass. Fourth, 
the sensitivities of the traditional single antigen assay and 
modified subclass-specific assay are different. Notable is that a 
minor proportion of antibodies detected using total IgG were not 
detected with any four subclass reagents. Antibodies <2000 MFI 
in the traditional single antigen bead assay can be negative in the 
subclass-specific assay (126, 129). Finally, a review of the literature 
shows that the methods for defining the threshold for positivity 
are vastly different (Table 2). While not diminishing the findings, 
these limitations, as well as the inherent semi-quantitative nature 
of the Luminex assay, do restrict the analyses to the presence or 
absence of IgG1–4 against a specific HLA antigen and currently 
do not reflect the titer or concentration of any subclass.
Another notable consideration is the variability of induction 
therapy among studies of IgG subclass distribution of HLA 
DSA, including basiliximab (129, 130), ATG (130), OKT3, 
thymoglobulin, or daclizumab (155). The impact of different 
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immunosuppression and induction therapies on isotype switch-
ing has not been thoroughly evaluated. What little is known is 
discussed below and suggests that both maintenance immu-
nosuppression and induction treatments influence B cell class 
switching.
B CeLL DiFFeReNTiATiON AND CLASS 
SwiTCHiNG
igG Subclasses in the Context  
of Protective immunity
Exposure to different types of antigens stimulates dramatic skew-
ing of IgG subclasses. Protein antigen leads to T-cell-dependent 
isotype switching to IgG1 and IgG3 that tend to dominate 
responses to viral and bacterial protein antigens. The impor-
tance of the diversity of Ig isotypes and subclasses is apparent 
from phenotypes of humans with selective subclass deficiencies, 
monoclonal gammopathy, and multiple myeloma. IgG3 or 
IgG1 deficiency increases susceptibility to bacterial respiratory 
tract infections. By the classical paradigm, bacterial and yeast 
polysaccharide antigens stimulate T-independent IgM responses 
and IgG2 production. Other evidence suggests that antibody 
responses to glycolipids and glycoproteins may obtain some help 
from the T cell compartment. IgG2 is predominantly produced 
in response to pneumococcal polysaccharides and encapsulated 
antigens (156, 157). The most infectious complications are seen 
in individuals with IgG2 deficiency, who demonstrate heightened 
susceptibility to respiratory bacterial infections, due to impaired 
responses to polysaccharides of encapsulated bacteria. IgG4 is 
often produced in settings of non-infectious immunity, such as 
allergy; immune therapy in beekeepers and allergic individuals 
promoted switching to IgG4 and relieved symptoms of allergy 
(158, 159). IgG4 is also produced in response to helminth and fila-
riasis parasitic infections (which, like allergy, also elicit IgE) (160, 
161). The clinical significance of deficiency of IgG4 is unclear.
Mechanisms of Class Switching
Immunoglobulins are tetrameric proteins composed of two heavy 
chains and two light chains connected by disulfide bonds. The 
IgG subclasses are numbered in order of abundance in circulation 
rather than order on the genome; in the human germline, the 
genes encoding the constant regions are ordered μ, δ, γ3, γ1, α1, 
γ2, γ4, ε, and α2. With the exception of membrane IgM and IgD 
in mature naïve B cells, a single B cell can only express one isotype 
of immunoglobulin at a time.
The genes encoding the various isotypes and subclasses are 
flanked by switch sites, each with its own promoter. The promot-
ers for the switch regions contain binding sites for cytokine-
responsive transcription factors, bridging exogenous signaling 
with isotype selection. Many cytokines, mostly Th2-associated, 
have been implicated in isotype and subclass specification, 
including IL-4, IL-13, IL-21, and IL-6 (162–165). However, no 
dedicated and unique switch factor has yet been identified for 
any given immunoglobulin heavy chain. Transcription of these 
switch regions produces a sterile germline RNA transcript (GLT). 
Subsequently, the variable region is joined with a downstream CH 
segment encoding a different Ig isotype to generate a new heavy 
chain (Figure 4).
Mature naïve B cells express membrane IgM and IgD. B 
cell activation is step-wise, and a simple schematic is shown in 
Figure 5. Formation of a synapse between T and B cells facili-
tates CD40–CD40L (CD154) interactions that prime the B cell. 
Cytokines signal the B cell to switch the isotype and subclass of 
immunoglobulin, and to secrete Ig. To isotype switch, the B cell 
must rearrange its DNA, linking the functional variable (VDJ) 
region of the heavy chain to one constant region heavy chain gene 
in a process called class switch recombination (CSR).
The first isotype of immunoglobulin that is produced is 
membrane-associated IgM (mIgM). IgM is also the first to be 
secreted upon B cell activation, as the switch from mIgM to 
secreted IgM requires only a change in mRNA splicing of the μ 
transcript to exclude the CH4 transmembrane domain. Upon 
primary exposure to an antigen, B cells will secrete IgM within 
4–5 days, peaking by about 1–2 weeks. Expression of IgG, IgA, 
and IgE, however, usually require further, division-linked, and 
genomic DNA rearrangement and do not appear until about a 
week after initial exposure. With a few exceptions, CSR is CD4 
T cell dependent.
Seminal work by Lechler and others demonstrated that immune 
recognition of allogeneic proteins occurs through three major 
pathways: direct, indirect, and semidirect allorecognition. The 
details of these pathways have been excellently reviewed elsewhere 
(166, 167). The direct pathway of allorecognition represents and 
important, although apparently transient (168, 169), mechanism 
of T cell response to solid organ allografts. Current paradigm 
holds that CD4 T cells recognize MHC class I alloantigens via the 
indirect pathway and are indispensable for alloantibody-mediated 
rejection (170–174). Shed alloantigens, including soluble MHC, 
may be taken up by host antigen-presenting cells, processed, and 
allopeptides presented in the context of host MHC II. Whole solu-
ble donor MHC stimulates a more robust alloantibody response 
than immunization with MHC peptides. B cells themselves are 
involved in the indirect presentation of donor antigen and activa-
tion of CD4 T cells (175, 176).
Given what is known about antibody isotype specification, how 
might alloreactive B cells be driven to form anti-HLA antibodies 
of a given IgG subclass? The cytokine milieu and availability of 
costimulation are critical for B cell antibody generation and the 
environment under which class switching occurs during trans-
plantation has yet to be explored experimentally. As mentioned 
above, it is conceivable that solid organ transplantation represents 
an extreme form of chronic antigen stimulation that ultimately 
results in the formation of IgG4 alloantibodies. One important fea-
ture of B cell activation unique to the post-transplant setting is that 
it occurs under the veil of maintenance immunosuppression. A 
few experimental studies have attempted to address the impact of 
immunosuppressive drugs on the mechanisms of class switching.
effects of immunosuppression
The frequency of DSA in patients with medication non-adher-
ence is much higher than in those without – ~70% at 12 years 
(1, 2, 177) – suggesting that current immunosuppressive regimens 
impact humoral allosensitization.
FiGURe 4 | Mechanisms of class switching. (A) In unswitched human B cells, the germline arrangement of heavy chain immunoglobulin genes is ordered by the 
variable region (VDJ) followed by the constant regions for IgM (Cμ), IgD (Cδ), IgG3 (Cγ3), IgG1 (Cγ1), IgA1 (Cα), IgG2 (Cγ2), and IgG4 (γ4). Each is flanked by a 
switch region (e.g., Sγ3). These regions are sites of transcription initiation and produce sterile germline transcripts (GLTs). (B) Transcription from the flanking switch 
regions is thought to make the DNA accessible to enzymes, such as activation-induced cytidine deaminase (AID), which facilitates recombination between switch 
regions, looping out the interior constant region genes. (C) In this example, the B cell is switching directly from IgM (dark blue) to IgG1, and the Cμ, Cδ, and Cγ3 
genes are removed so that the variable region can be directly fused with the Cγ1 region to form the IgG1 molecule (orange). Thus, B cells which are isotype 
switched can only further isotype switch the remaining subclasses downstream. Cγ4 is terminal.
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In rodents, mycophenolate mofetil (MMF) treatment signifi-
cantly altered IgG subclass distribution and reduced autoantibody 
production and development of systemic autoimmunity (178, 
179). In an in vitro study with human T and B cells, cyclosporine, 
mycophenolic acid (MPA), rapamycin, and, to a lesser extent, 
tacrolimus inhibited T cell proliferation; however, activation of T 
cells, as measured by CD25 and CD69, was unaffected. All of these 
drugs slightly dampened CD154 (CD40L) expression but signifi-
cantly reduced Tfh cell differentiation and suppressed cytokines 
implicated in B cell help (180, 181). However, if T cells were first 
activated and then subsequently exposed to immunosuppression, 
only rapamycin and MPA prevented IgM production by B cells. 
Therefore, memory T cells may still be capable of stimulating 
B cell responses even under suppression by tacrolimus (180).
In mice, costimulation of T cells through B7-1 (CD80) 
and B7-2 (CD86) are critical for antibody responses and 
particularly for IgG isotype switching via a non-redundant 
role with CD40 (182). Belatacept is a CTLA-4 fusion protein 
that blocks T cell costimulation via B7. In a non-human pri-
mate transplant model, costimulatory blockade with CTLA-4 
fusion proteins reduces de  novo alloantibody production in 
mice and non-human primate models (183–185). In human 
renal transplant recipients, the BENEFIT trial revealed that 
lowly HLA-sensitized patients treated with Belatacept had 
lower reduced frequency of de  novo donor-specific antibody 
production compared with the control cyclosporine arm (186, 
187). The B cell compartment in Belatacept-treated recipients 
was skewed toward naïve and transitional phenotypes (188). 
It is notable that patients in these trials were either DSA-free 
or low risk for preformed HLA DSA (186,  187). The impact 
of Belatacept on B cell activation and isotype switching in 
allosensitized patients might be less efficacious due to reduced 
FiGURe 5 | Activation of naïve B cells. Upon encountering cognate antigen through the membrane-associated IgM BCR, engagement of the BCR triggers 
intracellular signaling. On its own, moderate BCR cross-linking is not sufficient to induce proliferation, but cells do upregulate costimulatory molecules, such as 
CD40 and B7 (CD80/CD86), and increase antigen processing and presentation. The B cell may internalize the antigen into endosomal vesicles (and downregulates 
surface IgM), enabling it to process and present the antigen in HLA. B cells upregulate HLA II, cytokine receptors, costimulatory molecules CD40, B7-1, and B7-2, 
enter the cell cycle, and increase expression of prosurvival genes, and protein translation machinery. T-dependent protein antigens can be internalized and 
processed into peptides for presentation to CD4 T helper cells in HLA molecules. CD4 T cells provide additional costimulation via CD40L and expression of 
cytokines, such as IL-21, IL-10, IL-13, or IL-4. Integration of the BCR, CD40, and cytokine signaling stimulates class switch recombination, and the B cell ultimately 
switches from production of only membrane IgM and IgD to secretion of other isotypes such as IgG. T-independent antigens, such as those with repetitive motifs, 
extensively cross-link the BCR but are difficult to internalize. Glycolipid or polysaccharide antigens cannot be presented in classical HLA molecules for CD4+ T cell 
help. Concurrent signals may derive from Toll-like receptor (TLR) stimulation by antigens, NKT or αβ T cell help, leading to enhanced B cell activation and secretion 
of IgM or IgG2.
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costimulation requirements of memory immune cells [dis-
cussed in Ref. (189)].
There is also evidence that immunosuppressive drugs might 
alter isotype switching via direct effects on B cells. Prior depletion 
of B cells using rituximab reduced IgM and IgG1 responses after 
vaccination early after treatment, with a durable inhibition of IgM 
seen 6–10 months after vaccination (190). mTOR is central to the 
ability of B cells to proliferate and regulates CSR, and rapamycin 
has an impact on IgG production and plasmablast differentiation 
(191). Leflunomide is an immunosuppressant often used off-label 
in transplant recipients with viremia, such as with CMV or BK 
virus. Leflunomide acts on both T and B cells through inhibition 
of the JAK/STAT pathway critical for B cell signaling. Leflunomide 
inhibits IgG production in rodents, including reduction of donor-
specific antibodies in transplant models (192, 193).
In summary, multiple immunosuppressive agents have been 
demonstrated to impact isotype switching by B cells in in vitro 
and animal models. However, definitive evidence from systematic 
trials in humans is lacking to demonstrate differential effects on 
donor-specific IgG subclass production.
CLOSiNG ReMARKS
Clinical experience confirms that all donor-specific antibodies 
are not created equal. ABMR is a wide spectrum of graft injury 
from complement-mediated hyperacute rejection, to histological 
injury without graft dysfunction, to fibrotic chronic rejection and 
vasculopathy. Whether further discrimination of pathogenic DSA 
can be provided by complement fixation in vitro or by identifying 
the subclass(es) present remains to be determined. A majority 
of individuals pre- and post-transplant exhibit antibodies against 
HLA that are a mixture of IgG subclasses. Cumulatively, studies 
to date indicate that donor-specific IgG3 may be most relevant to 
acute antibody-mediated injury, while IgG4 DSA might signify 
alloimmune memory and correlate with subclinical and chronic 
rejection. However, IgG1 is also found in nearly all cases, indicat-
ing that heterogeneous subclass responses are the norm. These 
studies highlight the complexity of the alloimmune response and 
underscore the constraints on interpreting the relevance of DSA 
subclass repertoire in graft outcome, since exclusive skewing of 
donor-specific antibodies to one single subclass is rarely observed.
Three challenges must be overcome in order to identify charac-
teristics of pathogenic DSA. First, laboratories are faced with the 
task of developing reliable, informative, and cost-effective assays 
that can detect differences in effector functions or other features 
of HLA antibodies. Second, the mechanisms of graft injury by 
different subclasses of HLA antibodies should be confirmed 
in experimental transplant models and in  situ in allografts. To 
date, we can only postulate that in the setting of transplantation, 
anti-HLA IgG3 and IgG1 might elicit extensive complement 
activation and ADCC, while IgG2 and/or IgG4 may induce only 
HLA signaling in the allograft with little complement activation 
or FcγR-mediated functions. Much of the knowledge of antibody 
effector functions is derived from infectious disease and auto-
immune and cancer research, but little work has evaluated the 
capacity of different human HLA IgG subclasses to elicit inflam-
mation and injury during ABMR. Finally, few interventions exist 
for the treatment of ABMR, and their impact on class switching 
of alloreactive B cells is mostly uncharacterized. Therapies might 
be designed to manipulate the humoral alloimmune response 
to produce one subclass rather than another, but more effort 
is needed to understand the details of isotype specification by 
cytokines and other signals.
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